159 related articles for article (PubMed ID: 31530218)
1. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
Chen X; Wang DD; Xu H; Li ZP
Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
[TBL] [Abstract][Full Text] [Related]
2. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
Chen X; Wang D; Xu H; Li Z
J Clin Pharm Ther; 2020 Apr; 45(2):309-317. PubMed ID: 31755126
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
4. Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics.
Chen X; Wang DD; Xu H; Li ZP
Expert Rev Clin Pharmacol; 2020 May; 13(5):553-561. PubMed ID: 32452705
[TBL] [Abstract][Full Text] [Related]
5. Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome.
Lu T; Zhu X; Xu S; Zhao M; Huang X; Wang Z; Zhao L
Pharm Res; 2019 Feb; 36(3):45. PubMed ID: 30719576
[TBL] [Abstract][Full Text] [Related]
6. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study.
Liu J; Guo YP; Jiao Z; Zhao CB; Wu H; Li ZR; Cai XJ; Xi JY
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):453-466. PubMed ID: 32170643
[TBL] [Abstract][Full Text] [Related]
8. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus Population Pharmacokinetic Model in Adult Chinese Patients with Nephrotic Syndrome and Dosing Regimen Identification Using Monte Carlo Simulations.
Liao M; Wang M; Zhu X; Zhao L; Zhao M
Ther Drug Monit; 2022 Oct; 44(5):615-624. PubMed ID: 36101928
[TBL] [Abstract][Full Text] [Related]
10. Wuzhi Tablet (
Li J; Chen S; Qin X; Fu Q; Bi H; Zhang Y; Wang X; Liu L; Wang C; Huang M
Drug Metab Dispos; 2017 Nov; 45(11):1114-1119. PubMed ID: 28864749
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients.
Du Y; Song W; Xiong X; Ge W; Zhu H
Xenobiotica; 2022 Mar; 52(3):274-283. PubMed ID: 35502774
[TBL] [Abstract][Full Text] [Related]
12. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
Cheng F; Li Q; Wang J; Zeng F; Zhang Y
J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
[TBL] [Abstract][Full Text] [Related]
14. Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients.
Yan L; Yang ZQ; Shi YY; Ren J; Yang CL; Wan ZL; Bai YJ; Luo LM; Wang LL; Li Y
Ann Transplant; 2019 Nov; 24():594-604. PubMed ID: 31712547
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.
Hao GX; Huang X; Zhang DF; Zheng Y; Shi HY; Li Y; Jacqz-Aigrain E; Zhao W
Br J Clin Pharmacol; 2018 Aug; 84(8):1748-1756. PubMed ID: 29637588
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation.
Chen X; Wang DD; Xu H; Li ZP
Transl Pediatr; 2020 Oct; 9(5):576-586. PubMed ID: 33209719
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real-world data.
Chen X; Wang DD; Xu H; Li ZP
Exp Ther Med; 2020 Aug; 20(2):1423-1430. PubMed ID: 32765671
[TBL] [Abstract][Full Text] [Related]
20. Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.
Teng F; Wang W; Zhang W; Qu J; Liu B; Chen J; Liu S; Li M; Chen W; Wei H
Biopharm Drug Dispos; 2022 Aug; 43(4):119-129. PubMed ID: 35180322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]